Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart FailureAnthony Tang, Jean L. Rouleau, George A. Wells et al.|New England Journal of Medicine|2010Cited by 1.8k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) TrialMarc A. Pfeffer, Bertram Pitt, Brian Claggett et al.|Circulation|2014Cited by 1k
Navigating the Crossroads of Coronary Artery Disease and Heart FailureMihai Gheorghiade, Robert O. Bonow, George Sopko et al.|Circulation|2006Cited by 405
The continuous heart failure spectrum: moving beyond an ejection fraction classificationFilippos Triposkiadis, Gilles W. De Keulenaer, Javed Butler et al.|European Heart Journal|2019Cited by 258
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trialHiddo J.L. Heerspink, Rey Isidto, Bergur V. Stefánsson et al.|Nephrology Dialysis Transplantation|2019Cited by 216